Comparison of methods trial for high-risk HPV

Diagnostic Cytopathology

Volumn 38, Issue 2, 2010, Pages 104-108

  Kurtycz, Daniel F I ^a,b   Smith, Michele ^a   He, Rong ^b   Miyazaki, Kayo ^a   Shalkham, John ^a  

^a WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cervical screening; HPV testing; Invader (cervista); Method comparison; Pap test

Indexed keywords

OLIGONUCLEOTIDE;

ARTICLE; CANCER SCREENING; CLINICAL EVALUATION; COLPOSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DNA RNA HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; KAPPA STATISTICS; LABORATORY TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

CYTODIAGNOSIS; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IN SITU HYBRIDIZATION; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; VAGINAL SMEARS;

EID: 74849118173     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21161     Document Type: Article

References (10)

1. Mayrand MH, Duarte-Franco E, Rodrigues I, et al.; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus papanicolaou screening test for cervical cancer. NEJM 2007;357:1579-1588.
2. Sherman M, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002;94:102-107.
3. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE; for the ALTS Group*. A Comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Path 2005;124:722-732.
4. Solomon D, Schiffman M, Tarone R; for the ALTS Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst 2001;92:293-299.
5. Ginocchio CC, Barth D, Zhang F. Comparison of the third wave invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA. J Clin Microbiol 2008;46:1641-1164.
6. Kwiatkowski RW, Lyamichev V, de Arruda M, Neri B. Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol Diagn 1999;4:353-64.
7. Schutzbank TE, Jarvis C, Kahmann N, Lopez K, Weimer M, Yount A. Detection of high risk papillomavirus DNA with commercial Invader® technology-based analyte specific reagents following automated extraction of DNA from cervical brushings in ThinPrep™ Media. J Clin Microbiol 2007;45:4067-4069.
8. Davis-Devine S, Day SJ, Freund GG. Test performance comparison of inform HPV and hybrid capture 2 high-risk HPV DNA tests using the SurePath liquid-based Pap test as the collection method. Am J Clin Pathol 2005;124:24-30.
9. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, Guyatt G; for the Evidence-Based Medicine Teaching Tips Working Group. Understanding and calculating kappa. Tips for teachers of evidence-based medicine. Can Med Assoc J 2004;171:1369-1373 (plus five supplemental pages, Online 1-9).
10. Mitka M. IOM: Harm from US uninsured crisis has impact on those without coverage. JAMA 2009;301:1425-1426.